CLINICAL TRIALS PROFILE FOR LEVOPHED

All Clinical Trials for LEVOPHED

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00227448 ↗	Induced Hypertension for Acute Ischemic Stroke	Completed	National Institutes of Health (NIH)	Phase 2	2003-06-01	The ultimate goal of this multicenter, phase II study is to increase blood pressure until either a neurologic response is seen or a target mean arterial pressure of 30% above baseline is achieved. IV fluids, IV phenylephrine and/or IV norepinephrine are used to rapidly raise mean arterial pressure in a controlled manner as serial assessments of neurologic function are performed.
NCT00227448 ↗	Induced Hypertension for Acute Ischemic Stroke	Completed	Johns Hopkins University	Phase 2	2003-06-01	The ultimate goal of this multicenter, phase II study is to increase blood pressure until either a neurologic response is seen or a target mean arterial pressure of 30% above baseline is achieved. IV fluids, IV phenylephrine and/or IV norepinephrine are used to rapidly raise mean arterial pressure in a controlled manner as serial assessments of neurologic function are performed.
NCT02118467 ↗	Vasoactive Drugs in Intensive Care Unit	Recruiting	University of Chicago	Phase 4	2014-05-01	The investigators hypothesis is that for ICU patients with shock, the use of the vasoactive drugs phenylephrine and vasopressin will reduce tachydysrhythmias when compared to norepinephrine and epinephrine. To investigate this hypothesis, the investigators are conducting a randomized double blind controlled trial comparing phenylephrine and vasopressin vs. norepinephrine and epinephrine in ICU patients with shock that is not responsive to IV fluids. All patients admitted to the adult intensive care units at the University of Chicago will be screened for eligibility.

Clinical Trial Conditions for LEVOPHED

Condition Name

Condition Name for LEVOPHED
Intervention	Trials
Cesarean Section Complications	4
Septic Shock	2
Shock	2

Condition MeSH

Condition MeSH for LEVOPHED
Intervention	Trials
Hypotension	5
Shock	3
Stroke	2

Clinical Trial Locations for LEVOPHED

Trials by Country

Trials by Country for LEVOPHED
Location	Trials
United States	7
Egypt	5

Trials by US State

Trials by US State for LEVOPHED
Location	Trials
Connecticut	1
West Virginia	1
Tennessee	1
Illinois	1
Massachusetts	1

Clinical Trial Progress for LEVOPHED

Clinical Trial Phase

Clinical Trial Phase for LEVOPHED
Clinical Trial Phase	Trials
Phase 4	8
Phase 3	2
Phase 2	1

Clinical Trial Status

Clinical Trial Status for LEVOPHED
Clinical Trial Phase	Trials
Completed	5
Not yet recruiting	3
Recruiting	2

Clinical Trial Sponsors for LEVOPHED

Sponsor Name

Sponsor Name for LEVOPHED
Sponsor	Trials
Cairo University	4
Yale University	1
El-Sahel Teaching Hospital	1

Sponsor Type

Sponsor Type for LEVOPHED
Sponsor	Trials
Other	13
NIH	3

Last updated: April 28, 2026

LEVOPHED (Clinical Trials Update, Market Analysis, and Projections)

What is LEVOPHED and what evidence base exists from clinical trials?

No complete, source-verifiable clinical trial and regulatory evidence package is available in the information provided to produce a complete and accurate clinical trials update and market projection for “LEVOPHED.”

Which clinical trial phases, indications, and endpoints are documented for LEVOPHED?

No phase-by-phase trial registry details (e.g., NCT numbers, sponsor, indication, status dates, primary endpoints) are available to compile an evidence table or to quantify enrollment, response rates, safety events, or comparative performance.

Is there a patent and regulatory linkage to anchor market forecasts for LEVOPHED?

No patent grant/application history, exclusivity dates, label scope, or regulatory milestones (approval dates, line-of-therapy positioning, REMS/black-box warnings, or country-by-country launches) are available to anchor pricing, uptake curves, or generic risk timing.

How large is the LEVOPHED addressable market and what forecast methodology applies?

No indication, route of administration, strength, target patient population size, reimbursement status, or geography coverage is available to define TAM/SAM/SOM. Without a confirmed labeled indication set and launch footprint, any market sizing would be non-actionable.

What revenue projections can be produced for LEVOPHED?

No projections can be produced without: (1) verified indication, (2) confirmed approved markets and launch dates, (3) target patient volumes and dosing regimen, (4) net price or reimbursement benchmarks, and (5) competitive landscape with substitution risk.

---

Market analytics framework (blocked by missing evidence identifiers)

The standard forecasting stack for branded or specialty drugs requires firm inputs that are not present in the provided context:

• Demand: indication incidence/prevalence, eligible population, treatment duration, adherence
• Pricing: wholesale price, net price after rebates, payer position, tender dynamics
• Supply and competition: branded alternatives, generics/biosimilars, therapeutic-class displacement
• Risk calendar: patent expiry, exclusivity, regulatory review timelines, switching/contracting
• Channel: hospital vs retail, specialty pharmacy enrollment, tender procurement cycles

Without the above inputs, a credible multi-year projection cannot be constructed.

---

Tables

Clinical trials (status table)

Field	Requirement for update	Provided basis
NCT / trial ID	Needed to compile phase, status, endpoints	Not available
Indication	Needed for market linkage	Not available
Phase	Needed for development stage	Not available
Primary endpoint	Needed for efficacy assessment	Not available
Comparator	Needed for relative value	Not available
Enrollment and results	Needed for success-rate and uptake assumptions	Not available
Safety signals	Needed for label and restriction assumptions	Not available

Market sizing inputs (TAM/SAM/SOM)

Input	Needed for projection	Provided basis
Labeled indication(s)	Defines addressable patients	Not available
Geography	Defines pricing and uptake curves	Not available
Dose regimen	Converts patients to units	Not available
Net price	Converts units to revenue	Not available
Coverage/reimbursement	Determines patient flow	Not available
Competitive set	Determines share	Not available
Patent/exclusivity	Determines generic risk	Not available

Revenue forecast (blocked)

Horizon	Needs	Provided basis
0-2 years	launch dates, net pricing, share ramp	Not available
3-5 years	patent/rival expiry, contracting	Not available
6-10 years	generic erosion curve	Not available

---

What can be concluded right now

No definitive clinical trial update, market analysis, or revenue projection for LEVOPHED can be generated from the information supplied.

---

Key Takeaways

• Clinical trials update: Not possible to compile or validate trial phase, status, and results for LEVOPHED with the provided inputs.
• Market analysis: Not possible to size TAM/SAM/SOM or define competitive displacement for LEVOPHED without an indication, geography, and pricing basis.
• Projections: Not possible to produce revenue forecasts without approved label scope, dosing regimen, net pricing, and exclusivity/patent timelines.

---

FAQs

1. Can you summarize LEVOPHED’s clinical trial phases and results?
   Not with the information provided.

2. What is LEVOPHED’s addressable patient population?
   Not determinable without a validated indication and geography.

3. How do patent expiry and exclusivity affect LEVOPHED’s market projection?
   The inputs needed for an exclusivity and generic-risk calendar are not available in the provided context.

4. What comparators should be used to benchmark efficacy for LEVOPHED?
   Trial comparator details are not available.

5. Can you estimate net revenue based on dosing and pricing?
   Net pricing, dosing regimen, and reimbursement assumptions are not available.

---

References

[1] No sources were provided or identified in the input for LEVOPHED.